Flerie

Flerie ROCE

The Return on Capital Employed (ROCE) of Flerie (FLERIE.ST) as of Oct 18, 2026 is -23.16 %. In the previous year, Return on Capital Employed (ROCE) was -2.64 % — a change of 777.50% (lower).

ROCE

-23.16 %

YoY

777.50%

Last updated:

In 2025, Flerie's return on capital employed (ROCE) was -23.16 %, a 777.50% increase from the -2.64 % ROCE in the previous year.

The Flerie ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-128.09 SEK
Jan 1, 2019
-82.36 SEK
Jan 1, 2020
-117.03 SEK
Jan 1, 2021
-26.64 SEK
Jan 1, 2022
-45.25 SEK
Jan 1, 2023
-44.95 SEK
Jan 1, 2024
-2.64 SEK
Jan 1, 2025
-23.16 SEK
The Flerie ROCE history
YEARROCEYoY
-23.16 %+777.50%
-2.64 %-94.13%
-44.95 %-0.67%
-45.25 %+69.85%
-26.64 %-77.24%
-117.03 %+42.10%
-82.36 %-35.71%
-128.09 %+83.01%
-69.99 %+212.43%
-22.40 %-44.11%
-40.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Flerie Stock analysis

What does Flerie do? Flerie AB, listed on the Stockholm Stock Exchange under the ticker FLERIE.ST, is a pharmaceutical company based in Solna, Sweden. The company has 6 employees and completed its initial public offering (IPO) on October 11, 2016. Flerie AB operates within the healthcare sector, specifically in the pharmaceuticals industry. The company's website is https://www.indexpharma.com/. Flerie AB is a parent company for InDex Pharmaceuticals AB and InDex Diagnostics AB. The company is engaged in the development of drugs for the treatment of diseases such as inflammation and cancer. It has a drug candidate named cobitolimod, which is intended for the treatment of ulcerative colitis. Additionally, Flerie AB develops a platform of patent-protected substances known as DNA-based ImmunoModulatory Sequences (DIMS), designed to treat various immunological diseases. The company also offers a diagnostic kit called DiBiCol, a PCR-based method that monitors seven biomarkers specific to ulcerative colitis or Crohn's disease from a single colonic biopsy. Shareholders of Flerie AB include SEB Venture Capital, Industrifonden, and NeoMed Management. The company's focus is on pharmaceutical development, with an emphasis on innovative treatments for inflammatory and immunological conditions. Flerie is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Flerie's Return on Capital Employed (ROCE)

Flerie's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Flerie's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Flerie's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Flerie’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Flerie stock

Return on Capital Employed (ROCE) of Flerie is -23.16 % in 2025.

Return on Capital Employed (ROCE) of Flerie changed from -2.64 % to -23.16 %, representing a 777.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Flerie since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Flerie with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Flerie

All Key Metrics — Flerie